{"name":"Arvinas Androgen Receptor, Inc.","slug":"arvinas-androgen-receptor-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ARV-110 in Combination with Abiraterone","genericName":"ARV-110 in Combination with Abiraterone","slug":"arv-110-in-combination-with-abiraterone","indication":"Prostate cancer","status":"phase_1"}]}],"pipeline":[{"name":"ARV-110 in Combination with Abiraterone","genericName":"ARV-110 in Combination with Abiraterone","slug":"arv-110-in-combination-with-abiraterone","phase":"phase_1","mechanism":"Androgen receptor inhibitor","indications":["Prostate cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNYjF5N2lVbjNNdlgxT2R3ZzZ1SVBlMnpyX1pnZUswLUVMRGRZMEt4Y0NJS2ZJX3dRRmZXSW9mMGp2UzljczN6UEdxQ0NGYTR2bVYydkQ5SzVxLUtfNmFhWG9vQlhER2ZDRXYyaHJZZFdTQmtZZWpSdGdOc3dtYVdyMUh1d2UydFB2WkdQeG5oeDZrb1ZEb0hOLWdacVZfeDZjbmE1OW1pMkp0OU13M05abHVfUUI5SmZJdV9uaTNwV2RCeURoSk1ScU5UVU9JZVZFWnlNUFc2ekJHN3ZaaHZFZlF5a21iZ3RyYkE2bTVwVmZIVGZPUDNZYUVvang?oc=5","date":"2026-02-11","type":"regulatory","source":"The Malaysian Reserve","summary":"PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight - The Malaysian Reserve","headline":"PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | Delv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQblI3dHlSX2xwN1ZVMk9HZ2VrdVdMbkktMWJlVmJXQVdiYy04bTBpN2dtU2wzOGpGM3NfQ0xLWU0wQTBKMURNM3pnUGx6Umt2WVVua2tKaW4tYl9LYTNiSU1CcEFWR2pIRFhUSGlQX0p1ZGtBNlp4R2NNc095VXptZkFPMWRyUkpxLVlJNFVnSm1GeGxPMnF1VjNRQ3ZxNll1VU9iMDl3?oc=5","date":"2026-01-13","type":"pipeline","source":"BioCentury","summary":"TAC to the future: Where induced proximity is pointing in 2026 - BioCentury","headline":"TAC to the future: Where induced proximity is pointing in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxOc0VPcXJsc2I4Sl9mRy1DcGpqMTcwaVgxSEw2TnRVSjVjNjRFeUZwSTRheTk3UW1oWjhJUUFLc3BncTRULTN1cVpiWlN4OUFKWUFjUk9ydG9GWXRLRi10bHhpX0JOeVJpaEFhYjc1aGtJNGRCdnNpZUxvTDlOUUp6ZUxwNW92Y0VFbkVYbnFRNHU1eXZ0VU9oSUI1bFlnMWJsSkZMNHFoejQxRVRiMDlWR2hrYXNqQWEzRTJtQWYyUDVZQ1NtMHZBb0xuNG9NbE1pVnhnbjN5MXNOWktFRTRSbVZRWVYxOVBLRE5KeUpudzcyN3RxRTF3bWpTWmRjM0lvQ2JCUmVBSEU0ZUVhaTd6UWRidGJNVDR1bXdpOGNWZGk0cVpPeWZjaFJMX3FackFU?oc=5","date":"2025-08-27","type":"pipeline","source":"prnewswire.com","summary":"Androgen Receptor Targeted Therapies Market Forecast: Key Trends and Growth Projections Across the 7MM During the Forecast Period (2025-2034) | DelveInsight - prnewswire.com","headline":"Androgen Receptor Targeted Therapies Market Forecast: Key Trends and Growth Projections Across the 7MM During the Foreca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxQQ3RBa2N5T3hEMktSWEJpMUpYYTNBTElsdkdST1JNc0FuNWVaNTZ0ck0zWXJkODBNTTR6NlhJOHdxMXcwWUhISnkwWk81YWtFTXJCRWw2cnFwQndFdkF3YjVlYWlTVmZTcm92SWNicVBRTS05OWo3TG1UOTlvNnN0VkVTNzJuZDloNjdCNkx1dkxfbjY4Y0NFSmhXRmpkMmV5RHpybDJvSDFwWmQ5ZmkxZTJwT05GU1pXRUpEZ29EdnlPNHVpOV92S0dVbmFrQQ?oc=5","date":"2024-05-19","type":"pipeline","source":"2 Minute Medicine","summary":"Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer - 2 Minute Medicine","headline":"Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer - 2 Minute Medicin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNN0JqMHRrWEhyeWltM20tcnZWQlJmWWZfUFV5UXozS2ZtaUEwMGR4cVRXWmxub2gxdWVfcUUxY3cybVZjZGJXdjN2RUV6Qm9OUGwwUkZ4TTQ1SUIxSmQzRUNrOFNWaWt4bVd5WmhlZEkxdjhOWFN3NWdLV1ppOTU5OXBn?oc=5","date":"2024-04-12","type":"deal","source":"Pharmaceutical Technology","summary":"Novartis enters deal for Arvinas’ prostate cancer therapy - Pharmaceutical Technology","headline":"Novartis enters deal for Arvinas’ prostate cancer therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNd2lQYXM0c0x3b096UHdKUlBrOWYxUlZtbEdJSFlZcXI4SG9OcG9WLW9iSE9hcWJfSjAtS3hwYTJKMHYxWkRyd3hCUno5YVZMTmduYWR4TkFydUtUUDhKb2h3MGVTVEZTTGhlMG9Oc1V3NUpuTi1OR09YX0RSV2xiLTdUdTBVUFNtNjhN?oc=5","date":"2024-04-12","type":"pipeline","source":"pharmaphorum","summary":"Novartis adds clinical-stage protein degrader from Arvinas - pharmaphorum","headline":"Novartis adds clinical-stage protein degrader from Arvinas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQMGhOcWg4QjJQV1BrYWJuMklZNkRZWWtMOGxkYmFsNldPT1ZRbGctYlh5c2gxa3MyeFFqcjRGVXRxRzdBOEZiaTJERzNZSVVubUpyYV9nVEEtS0lVX29HaEJ0R0FEV0M1QWJkX184R0wwa0ZQTXNQTDV5MW0xTnMtbjF3eE9XQTQ1bWFhTERXV0c?oc=5","date":"2024-04-11","type":"trial","source":"Oncology Pipeline","summary":"Arvinas degraders get another vote of confidence | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Arvinas degraders get another vote of confidence | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOaUVvQ1ZfOXdKSXRjZURPRmpuNUw2Vm0zeWVURFcxNUdoMWhrcld4YXMzN2pwYlQ5Mm1yeFpKakVkbFFNTnhiNTVOc0kxSXNfZDBnenhwdUJyT0s2ckh0a0c5NHhQRm5EUjMxUndiazBUNmdZclh2dEhSSmstVHhQYzdiVmpCNklsM2dZbHp6UUlRaktKVGwySjlB?oc=5","date":"2024-04-11","type":"trial","source":"MedCity News","summary":"Novartis Pays $150M to Nab a Phase 3-Ready Protein Degrader for Prostate Cancer - MedCity News","headline":"Novartis Pays $150M to Nab a Phase 3-Ready Protein Degrader for Prostate Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQRE5ReHRvT21Qc3FLczE2dnI3eWstQnl3end1S245eUxGR3pGVUpJRC1Iby1fRDNxd0I2NTZ1ZFEtQ201dFl3Y0otc3ZNVWxrYTY1dG5sTDViYWNNNjN1VHpBS3ZMY2NXdVNHbTRoaFpDX3FiYlh2YVI2NFl5ZUszaW9rdkVfWUtvWjI5bjNITHZoWHZiTW5EVWVDZ1pJQ1pjVVkyUVRlX2pwTk5oSFVudUFncy00VjQ?oc=5","date":"2024-04-11","type":"deal","source":"BioSpace","summary":"Novartis Inks $1B Protein Degrader Deal with Arvinas, Begins MorphoSys Tender Offer - BioSpace","headline":"Novartis Inks $1B Protein Degrader Deal with Arvinas, Begins MorphoSys Tender Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AJBVV95cUxPeTBrMm93aGpCSDlYOTFhTmZ5RlBPZzhHWVpucE1RX000MFNIblUwcXpURXZLcjJSN2ExeUJSelRTY3daYnQ4cEFNQk1WYldRNDdEblRDeVV5b2puLU5zbDVfLTV1eDdoS3dnaGpqWFloaDgtYnEtUGkzWWh6RzR4cEo2ampxbFNIaWVLb0RjRngyX0xpSnBETWQzZXJRd3V5RWp0cFVSclYybXBSbEdVVWU2MkNNVEo5VGxxXzBOek9FQUtWTGlZNEtZZHRzWFBMS2pMX3B0V2stN0VzM0tKQnRwUzFrelc0U1RQXzJST05pN0Z1X0hMbVNkbTI5eS1JbmFmV21GdnQtSWY3bDdtdjB0cXA4clFyV3o0ZW9mYVlheTE0RUlESmp0cUVkY3dtN0ZPc3hVYl9QZHcxR1BTOG1WZnF3MmJGQnU4M0lGMnBGeURyMTN6TWxYR2QtanR6bTgxUG1iWjgtMklJ?oc=5","date":"2024-04-11","type":"pipeline","source":"GlobeNewswire","summary":"Arvinas Enters into a Transaction with Novartis, including - GlobeNewswire","headline":"Arvinas Enters into a Transaction with Novartis, including","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOMk5uRE9VbUtWSHVnMjVlSnB6TWxEeGIwYW9ac0FZZG5VZmRuM2stSTVfTEkzS2dYSEpIV3VyamZKSEZzbG1EcUZXUlJvYmZPWldvbUZZT1hhempnTXdla2UwSVNyTFQ3c1dEaWpFZEtablFzRDhsU1hGdFJKekRobEY0dGFGbUpyVGdSTnlQWVVmREZUQWc?oc=5","date":"2021-04-14","type":"pipeline","source":"C&EN","summary":"Arvinas unveils PROTAC structures - C&EN","headline":"Arvinas unveils PROTAC structures - C&EN","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPWVlHOWtHQ2wwMS1WVERKQm1PSHNnSWhMM1VJWFlvOVJrYWpCajZFekVybS0zNHhfYzEybzhINERHRW5tWnBnZURablZSaUdzMXdEX1FKbmd0Y1B5NXlLRjBBTG9YSnNCR3FscGdkWGVtZ18xdnlBdGktUHpWVlN3MWNoanNZOURhNHdiaEJKVW54dDRQLXNFUV9zVHF2Y1lBTGt3M1F1ZFN0bEFQMjY1SXNLdkNINzZqMk5z?oc=5","date":"2020-12-14","type":"pipeline","source":"Fierce Biotech","summary":"Arvinas eyes a busy 2021 as protein degraders gather steam in breast, prostate cancers - Fierce Biotech","headline":"Arvinas eyes a busy 2021 as protein degraders gather steam in breast, prostate cancers","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}